Science Will Win

What comes after a cancer diagnosis and treatment?

In this episode of Science Will Win, host Dr. Raven Baxter explores one of the most important, and often overlooked, chapters for cancer patients: survivorship. As five-year survival rates climb to 70%, more people than ever are living with and beyond cancer. But longer survival brings its own complex challenges, and our care systems are still catching up.

You'll hear from experts ...

What women carry through cancer is more than a diagnosis. 

In our third episode of this miniseries, Dr. Raven Baxter explores how generations of women turned silence into advocacy and fear into progress, reshaping the perceptions and discussions around cancer over time. Through history, science, and a powerful story from Katrina M. Johnson — a woman who has lived through multiple breast cancer diagnoses and now advocates for others...

What if the key to treating cancer was hiding in plain sight – written into its DNA? In this episode of Science Will Win, host Dr. Raven Baxter explores one of the most exciting breakthroughs in cancer care today: the discovery of biomarkers. These tiny molecular signals are helping doctors understand what’s really driving an individual person’s cancer – and opening the door to treatments that can dramatically change patient outcom...

Why are more young adults getting cancer? That's one of the most pressing questions facing the scientific community today. Traditionally thought of as a disease that affects aging populations, recent data shows that cancer diagnoses for people under the age of 50 are increasing. To tackle this problem, it’ll take a global effort. In this episode you’ll hear from patients, oncologists, researchers and health care providers who are c...

Science Will Win is back for a new season! Dr. Raven Baxter, a molecular biologist also known as Raven the Science Maven, returns as our host to dive into the latest in oncology: The latest challenges, the latest research, the latest treatment approaches, and the latest sources of progress and optimism keeping researchers going. You’ll hear from leading doctors, cutting-edge scientists, insightful historians, and inspiring patients...

In drug discovery and development, every part of the process matters. Scientists learn from every experiment and every observation. In fact, some of the most cutting-edge advancements in medicine are being dreamed up from findings uncovered in the past.  

In this episode, co-hosts Dr. Raven Baxter and Dr. Ronald Gamble dive deep into antibody drug conjugates, a groundbreaking modality that uses targeted antibody engineering to deliv...

Protein-protein interactions facilitate numerous bodily processes – everything from the basics of how our muscles contract to the more complex ways cancer can spread through the body. So, what if there was a way to alter some of these interactions? Or even create new ones?

In this episode, we’re diving into the fascinating field of molecular glues, a revolutionary modality on the precipice of changing the treatment landscape for cer...

The next frontier of medicine is focused on highly targeted drug therapies that could expand the possibilities of individualized patient care. Today, scientists are working on a particular type of molecule that could harness multiple capabilities and treat inflammatory and autoimmune diseases in ways never done before. 

In this episode, co-hosts Dr. Raven Baxter and Dr. Ronald Gamble explore how the latest advancements in antibody e...

Medical advancements don’t just spring up—they happen by building on decades of previous discoveries. Today, one of these advancements might be on the verge of another breakthrough. But what had to happen first for it to exist?

In this episode, co-hosts Dr. Raven Baxter and Dr. Ronald Gamble explore how a vaccine candidate for a deadly, once-mysterious bacterial disease came to be. The story takes them from one doctor’s groundbreaki...

Science Will Win is back for a new season, with new hosts and a new format. Now, science educators Dr. Raven Baxter a molecular biologist otherwise known as Raven, the Science Maven, and Dr. Ronald Gamble, a theoretical astrophysicist at NASA, are teaming up to explore four exciting medical technologies. These technologies are right on the cusp of a potentially groundbreaking moment, either unlocking our ability to tackle new disea...

Over the last five years, the healthcare industry has witnessed an explosive surge in digital health services, revolutionizing the way we access medical care. Patients today are taking charge of their health journey by using different digital tools to stay on top of their preventative screenings, implement dietary and lifestyle changes, access mental health resources, and so much more. In this conversation, patient advocates and in...

While cancer deaths in the United States have declined in recent years, some populations are being left behind—facing complicated challenges to accessing the care they need. Intervening at the earliest stages of disease onset is critical to cancer treatment success and to reducing the risk of recurrence. So how do we create a world where all people with cancer are quickly diagnosed and can live better, longer lives as science advan...

Podcasting has become essential for communicating breakthroughs in science, offering an accessible and engaging platform to reach diverse audiences. This evolving medium fosters deeper connections by delivering trusted information in accessible and compelling ways. In this conversation, audio makers from Pfizer, Acast, and TED, discuss what it takes to stand out in the science podcast space, insights on strategy, and how they're wo...

So far in this season, we’ve explored how innovations throughout history have brought us to where we are now. We talked about how drug discovery changed from a serendipity-based to data-based endeavor. Then, we explored the powerful hardware and smart software required to accommodate big data. Now, the door to the future of AI in drug discovery is open. In our final episode, we’re looking toward the future, to understand where toda...

With a trove of data and powerful hardware to process it, software is the last element of our artificial intelligence story. In this episode, host Jeremiah Owyang and expert guests explore the history of advancement behind the software that powers AI today. They delve into the creation of neural networks at the heart of this technology and how scientists are partnering with AI to revolutionize the complex process of drug developmen...

Last episode discussed data and how crucial large swaths of data are in assisting drug development. But more data requires a lot of storage – and that’s where hardware comes in. To make use of big data and all its possibilities, scientists need new tools at their disposal. In this episode, host Jeremiah Owyang, alongside expert guests, traces the rise of large-scale computational resources used throughout the medical industry today...

The intersection of biology and technology is revolutionizing drug discovery. In this episode, host Jeremiah Owyang and expert guests explore the crucial role of data in advancing medical science, from the serendipitous discoveries of the past to the cutting-edge techniques of today. They delve into the history of drug development, the rise of "omics," and the innovative single-cell sequencing that is transforming our understanding...

Artificial intelligence has the potential to help save millions of lives by accelerating the discovery and development of treatments for humanity’s toughest diseases. Those AI innovations come down to three key factors: data, hardware, and software. Science Will Win Season 4 takes listeners on a journey back in time to learn how each of these three elements got where it is today. Each episode features interviews with historians and...

Throughout history, humans have coalesced around moonshot culture to achieve audacious goals—from eradicating smallpox, to sequencing the human genome, to landing a spacecraft on Mars. These feats of human ingenuity didn’t happen in a vacuum, they were born from intentional innovation, a “coalition of the willing,” and a vision to outdo yesterday. This fireside chat with Drew Panayiotou, Former CMO of Pfizer and Devon Still, ex-NFL...